Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Carbonic Anhydrases in Sarcoma: Resetting the Tumor's Survival Script.

Created on 29 Oct 2026

Authors

Daria R Fayzullina, Nina P Loginova, Alina R Navruzbekova, Peter S Timashev, Ilya V Ulasov

Published in

Journal of cellular physiology. Volume 241. Issue 10.

Abstract

Carbonic anhydrases (CA) are zinc-containing metalloenzymes that catalyze the reversible hydration of carbon dioxide, playing a central role in pH homeostasis. In aggressive sarcomas, including osteosarcoma and Ewing sarcoma, specific CA isoforms are exploited to establish a pH gradient characterized by an alkaline cytoplasm and acidic extracellular microenvironment. This gradient promotes tumor cell survival under hypoxia, facilitates invasion and metastasis, and drives resistance to conventional therapies. High levels of CA II and CA IX expression are associated with worse 5-year survival in patients diagnosed with Ewing Sarcoma and osteosarcoma, respectively. Carbonic anhydrase inhibitors have evolved from non-selective sulfonamides to isoform-selective agents, such as the clinically advanced SLC-0111, which preferentially targets CA IX. Beyond direct cytotoxicity, carbonic anhydrase inhibitors exert multifaceted antitumor effects: they reverse pathological pH gradients, overcome pH-dependent chemoresistance, suppress invasive potential, and induce distinct cell death pathways including apoptosis and ferroptosis. Thus, CA inhibitors hold considerable promise for use in combination therapy, especially chemotherapy and immunotherapy. Clinical trials of CA inhibitors in advanced solid tumors have established favorable safety profiles, supporting their evaluation in CA-enriched sarcoma populations. This review summarizes the mechanistic rationale for targeting carbonic anhydrases in osteosarcoma and Ewing sarcoma, highlighting the therapeutic potential of CA inhibitors as part of combination regimens to overcome treatment resistance and improve patient outcomes.

PMID:
42950082
Bibliographic data and abstract were imported from PubMed on 29 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 10
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement